Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 13/20 | 0.56 |
| ▸ | DRD1 | P21728 | 7/20 | 0.56 |
| ▸ | DRD2 | P14416 | 5/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1039709 | 0.89 | DRD3 (0.63) | DRD3DRD1DRD2ACHEDRD4 | |
| SCHEMBL1037156 | 0.88 | DRD3 (0.62) | DRD3DRD1DRD2ACHEDRD4 | |
| SCHEMBL30183479 | 0.83 | DRD3 (0.53) | DRD3DRD1DRD2ACHENPC1 | |
| SCHEMBL7686132 | 0.83 | DRD3 (0.53) | DRD3DRD1DRD2ACHENPC1 | |
| SCHEMBL5636228 | 0.83 | KDM4E (0.64) | DRD3DRD2ACHENPC1ALDH1A1 | |
| SCHEMBL30183548 | 0.81 | DRD3 (0.57) | DRD3DRD1DRD2ACHEDRD4 | |
| SCHEMBL19852206 | 0.81 | DRD3 (0.54) | DRD3DRD1DRD2ACHENPC1 | |
| SCHEMBL3653396 | 0.81 | HRH3 (0.69) | DRD3DRD1DRD2HRH3 | |
| SCHEMBL31134854 | 0.81 | GRM5 (0.64) | DRD3DRD1DRD2ACHENPC1 | |
| SCHEMBL5380985 | 0.81 | DRD3 (0.57) | DRD3DRD1DRD2ACHEDRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020068827-A1 | Quinoline-4-carboxamide derivatives, their preparation and their use as neurokinin 3 ( NK-3 ) - and neurokinin 2 ( NK-3 ) receptor antagonists | SMITHKLINE BEECHAM S.P.A. | 2002-06-06 | — | — | US | disclosed |
| EP-1019377-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS NEUROKININ 3 (NK-3)- AND NEUROKININ 2 (NK-2) RECEPTOR ANTAGONISTS. | Smithkline Beecham S.p.A. (IT) | 2000-07-19 | — | — | EP | disclosed |
| WO-1997019926-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS NEUROKININ 3 (NK-3)- AND NEUROKININ 2 (NK-2) RECEPTOR ANTAGONISTS. | SMITHKLINE BEECHAM S.P.A. (IT) | 1997-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068827-A1 | Quinoline-4-carboxamide derivatives, their preparation and their use as neurokinin 3 ( NK-3 ) - and neurokinin 2 ( NK-3 ) receptor antagonists | TAC3, TACR2, TACR1 | DRD3 165/4885DRD1 430/4885DRD2 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.